Scholars Central

Conference abstractPublished 25 Aug 2015

Using Transcriptomics to Guide Lead Optimization in Drug Discovery Projects: Lessons Learned from the QSTAR Project

Authors: Gunter Klambauer

Johannes Kepler University Linz, Austria

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The pharmaceutical industry is faced with steadily declining R&D efficiency, and as a result, every year fewer new drugs reach the market despite increased investment. One major cause for this low efficiency is the frequent failure of drug candidates in late-stage development due to safety issues or previously undiscovered side effects. The question now arises which compounds to advance through early phases, in particular during lead optimization, based on the limited data available at these stages. High-throughput techniques for measuring transcripts are perfectly suited towards addressing this question. First attempts have already been made to identify compound-induced perturbations in transcriptomics networks with the aim of understanding biology and mechanisms of action. However, the utility of gene expression profiling for decision-making in early-stage pharmaceutical drug discovery has not yet been demonstrated. In this work, and for a series of eight drug discovery projects within a global pharmaceutical company, we analyzed to what extent gene expression data can help with decision-making during lead optimization across disease areas, targets and scaffolds. Disease areas included oncology, metabolic diseases, virology, and neuroscience. In three projects, gene expression data were clearly able to support “go/no-go” decisions. In three other projects the observed transcriptional effects were biologically relevant but their contribution to the decision-making process was limited. Overall, our studies show that gene-expression profiling is a powerful technique for the detection of adverse effects of compounds, and a valuable tool in early-stage drug discovery decision-making.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectGenetics & Molecular Biology
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Gunter Klambauer”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels